Trident Texofab Ltd Falls to 52-Week Low of Rs.112.9 Amid Continued Downtrend

Stock Price Movement and Market Context

On 17 Feb 2026, Trident Texofab Ltd opened sharply lower at Rs.112.9, representing a day’s decline of 4.97%. This opening gap down set the tone for the session, with the stock trading steadily at this level throughout the day and hitting an intraday low that matched the opening price. The current price is a stark contrast to its 52-week high of Rs.379, underscoring a steep depreciation of over 70% from its peak.

The stock has been on a continuous downward trajectory for 21 consecutive trading days, resulting in a cumulative loss of 58.71% over this period. This sustained decline has contributed to a one-year return of -35.80%, significantly lagging behind the Sensex’s positive 9.58% return over the same timeframe. The Sensex itself is trading near its 52-week high, up 0.02% today at 83,291.04, highlighting the divergence between the broader market and Trident Texofab’s performance.

Further technical indicators reveal that the stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a bearish trend across multiple time horizons. This technical weakness aligns with the stock’s underperformance relative to its sector peers and the broader market.

Financial Performance and Valuation Metrics

Trident Texofab’s recent quarterly results have been subdued, with net sales for the December 2025 quarter reported at Rs.25.74 crores, marking the lowest quarterly sales figure in recent periods. This flat sales performance has contributed to the stock’s diminished appeal among market participants.

From a fundamental perspective, the company’s long-term financial health remains a concern. The average Return on Capital Employed (ROCE) stands at a modest 6.88%, indicating limited efficiency in generating returns from its capital base. Additionally, the company’s debt servicing capacity is constrained, with a high Debt to EBITDA ratio of 6.83 times, reflecting elevated leverage and potential financial strain.

Despite these challenges, the company’s valuation metrics suggest a degree of fairness relative to its capital employed. The ROCE for the latest period is slightly improved at 7.4%, and the Enterprise Value to Capital Employed ratio is 2.4, which is considered reasonable within the industry context. The stock is trading at a discount compared to the average historical valuations of its peers, which may reflect market caution given the company’s recent performance.

Comparative Performance and Market Position

Over the past three years, Trident Texofab has consistently underperformed the BSE500 index across multiple timeframes, including the last three months, one year, and three years. This trend highlights persistent challenges in maintaining competitive growth and profitability within the Garments & Apparels sector.

While the company’s profits have increased by 122.5% over the past year, this improvement has not translated into positive stock returns, as reflected by the PEG ratio of 1.1. This ratio suggests that the stock’s price does not fully reflect the earnings growth, possibly due to concerns over sustainability and financial leverage.

Majority shareholding remains with non-institutional investors, which may influence liquidity and trading dynamics. The company’s Mojo Score stands at 20.0, with a Mojo Grade of Strong Sell as of 3 Feb 2026, an upgrade from the previous Sell rating. This grading reflects the assessment of the company’s fundamental and market performance factors.

Sector and Market Environment

The Garments & Apparels sector has experienced mixed performance in recent months, with some companies benefiting from renewed demand and others facing headwinds due to cost pressures and competitive dynamics. Trident Texofab’s current valuation and price action suggest that it is among the more challenged names within the sector.

Meanwhile, the broader market environment remains relatively stable, with the Sensex trading close to its 52-week high and mega-cap stocks leading gains. This divergence underscores the stock-specific factors influencing Trident Texofab’s performance rather than broader market trends.

Investors and market participants will continue to monitor the company’s financial metrics and market behaviour as it navigates this period of subdued performance and valuation pressures.

Unlock special upgrade rates for a limited period. Start Saving Now →